CVS · Company research
CVS HEALTH CORPORATION (CVS): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
39records availableConsumer
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Applied AI Company Baba Raises $40 Million Series A to Improve the Medicare Experience | Baba, an applied AI company modernizing Medicare and Medicaid care, announced a $40 million Series A funding round led by FirstMark Capital with participation from CVS Health Ventures and Valtrius. The funding will support expansion of clinical care teams, AI research advancement, and health plan partnerships. Baba provides dedicated care coordination combining licensed clinicians, care coordinators, and AI to help patients navigate complex healthcare needs, currently serving over 10,000 patients with 100,000 families on waitlist. | View source ↗ | GlobeNewswire Inc. | Oct 20, 2026 | bullish | 1 | 1 |
| Can Molina Healthcare Overcome Lower Premiums and Higher MCR in Q3? | Molina Healthcare is projected to report a 60.9% earnings decline in Q3 2026 with revenues falling 4.8%. The company faces multiple headwinds including a 12.7% membership decline (63% drop in Marketplace enrollment), rising medical care ratio to 93%, and falling premium revenues and investment income. The stock has a negative Earnings ESP of -3.30% and Zacks Rank #4 (Sell), making an earnings beat unlikely. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.5 | 1 |
| How to prepare your household for cold and flu season - CVS Health | How to prepare your household for cold and flu season CVS Health | View source ↗ | CVS Health | Oct 16, 2026 | neutral | 0 | 0.6 |
| CVS Caremark Is Transforming the Health Care Experience - Yahoo Finance | CVS Caremark Is Transforming the Health Care Experience Yahoo Finance | View source ↗ | Yahoo Finance | Oct 16, 2026 | neutral | 0 | 0.6 |
| Dividend Roundup: Johnson & Johnson, Coca-Cola, Costco, CVS Health, and more - Seeking Alpha | Dividend Roundup: Johnson & Johnson, Coca-Cola, Costco, CVS Health, and more Seeking Alpha | View source ↗ | Seeking Alpha | Oct 16, 2026 | neutral | 0 | 0.6 |
| Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock? | Danaher Corporation is expected to report Q3 2026 revenues of $26.3 billion, up 8.2% year-over-year, driven by strength in Biotechnology, Diagnostics, and Life Sciences segments, plus the Masimo acquisition. However, rising input costs, product mix changes, and currency headwinds may pressure profits. The company has a positive Earnings ESP of +0.30% and Zacks Rank of 2 (Buy). | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock? | Danaher Corporation is expected to report Q3 2026 revenues of $26.3 billion, up 8.2% year-over-year, driven by strength in Biotechnology, Diagnostics, and Life Sciences segments, plus the Masimo acquisition. However, rising input costs, product mix changes, and currency headwinds may pressure profits. The company has a positive Earnings ESP of +0.30% and Zacks Rank of 2 (Buy). | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| CVS Health Corporation $CVS Stock: Community Trust & Investment Co. Cuts Holdings - MarketBeat | CVS Health Corporation $CVS Stock: Community Trust & Investment Co. Cuts Holdings MarketBeat | View source ↗ | MarketBeat | Oct 16, 2026 | neutral | 0 | 0.6 |
| CVS Health Corporation $CVS Stock Sold by Curated Wealth Partners LLC - MarketBeat | CVS Health Corporation $CVS Stock Sold by Curated Wealth Partners LLC MarketBeat | View source ↗ | MarketBeat | Oct 16, 2026 | neutral | 0 | 0.6 |
| CVS Health Corporation $CVS Stock Acquired by Assenagon Asset Management S.A. - MarketBeat | CVS Health Corporation $CVS Stock Acquired by Assenagon Asset Management S.A. MarketBeat | View source ↗ | MarketBeat | Oct 16, 2026 | neutral | 0 | 0.6 |
| Elevance Q3 Earnings Preview: Will Lower Premiums Weigh on Results? | Elevance Health is projected to report Q3 2026 earnings on October 21, 2026, with consensus estimates showing a 22.7% year-over-year EPS decline to $4.66 per share and a 3% revenue decrease. The company faces challenges from declining premiums (-4.9%), reduced Commercial Individual and Medicaid membership, and a significant 23.9% plunge in Health Benefits operating income. Despite these headwinds, total expenses are expected to decline 5.5%, providing some offset. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.5 | 1 |
| Elevance Q3 Earnings Preview: Will Lower Premiums Weigh on Results? | Elevance Health is projected to report Q3 2026 earnings on October 21, 2026, with consensus estimates showing a 22.7% year-over-year EPS decline to $4.66 per share and a 3% revenue decrease. The company faces challenges from declining premiums (-4.9%), reduced Commercial Individual and Medicaid membership, and a significant 23.9% plunge in Health Benefits operating income. Despite these headwinds, total expenses are expected to decline 5.5%, providing some offset. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.5 | 1 |
| CVS Health collaborates with The Midlife Collective to redefine a woman's midlife health journey - PR Newswire | CVS Health collaborates with The Midlife Collective to redefine a woman's midlife health journey PR Newswire | View source ↗ | PR Newswire | Oct 15, 2026 | neutral | 0 | 0.6 |
| MinuteClinic earns 7th Joint Commission accreditation | CVS Stock News - Stock Titan | MinuteClinic earns 7th Joint Commission accreditation | CVS Stock News Stock Titan | View source ↗ | Stock Titan | Oct 14, 2026 | neutral | 0 | 0.6 |
| CVS vs. ALHC: Which Medicare Advantage Stock Is the Better Pick Now? | CVS Health and Alignment Healthcare are competing in the fast-growing Medicare Advantage market, projected to expand at 10.1% CAGR through 2034. CVS is successfully turning around Aetna with over $2 billion in adjusted operating income gains in H1 2026, while Alignment Healthcare grew membership 31.5% but faces headwinds from higher medical needs among new members. CVS trades at a lower forward P/E (10.41 vs 25.43) with positive earnings revisions, while Alignment faces downward estimate revisions and a 50.8% stock decline over the past year. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | neutral | 0 | 1 |
| CVS vs. ALHC: Which Medicare Advantage Stock Is the Better Pick Now? | CVS Health and Alignment Healthcare are competing in the fast-growing Medicare Advantage market, projected to expand at 10.1% CAGR through 2034. CVS is successfully turning around Aetna with over $2 billion in adjusted operating income gains in H1 2026, while Alignment Healthcare grew membership 31.5% but faces headwinds from higher medical needs among new members. CVS trades at a lower forward P/E (10.41 vs 25.43) with positive earnings revisions, while Alignment faces downward estimate revisions and a 50.8% stock decline over the past year. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | neutral | 0 | 1 |
| Is CVS Health (CVS) Undervalued As Aetna Wins Medicare Advantage Stars And Pharmacy Growth Expands? - Simply Wall Street | Is CVS Health (CVS) Undervalued As Aetna Wins Medicare Advantage Stars And Pharmacy Growth Expands? Simply Wall Street | View source ↗ | Simply Wall Street | Oct 14, 2026 | neutral | 0 | 0.6 |
| CVS Health Unit to Pay $315 Million to Resolve Illegal Opioid Prescription Claims - WSJ | CVS Health Unit to Pay $315 Million to Resolve Illegal Opioid Prescription Claims WSJ | View source ↗ | WSJ | Oct 13, 2026 | neutral | 0 | 0.6 |
| How to Find Strong Medical Stocks Slated for Positive Earnings Surprises | The article explains how investors can use the Zacks Earnings ESP (Expected Surprise Prediction) filter to identify stocks likely to beat earnings expectations. The ESP compares the most accurate analyst estimates to consensus estimates, and when combined with a Zacks Rank #3 or better, stocks posted positive surprises 70% of the time with average annual returns of 28%. Two medical stocks highlighted as examples are Gilead Sciences (GILD) with a +2.18% ESP and CVS Health (CVS) with a +0.79% ESP, both holding Rank #3 (Hold) ratings. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bullish | 1 | 1 |
| CVS Health (CVS) Stock Looks Reasonable On Fresh Vaccine Access News - Simply Wall Street | CVS Health (CVS) Stock Looks Reasonable On Fresh Vaccine Access News Simply Wall Street | View source ↗ | Simply Wall Street | Oct 10, 2026 | neutral | 0 | 0.6 |
| Jim Cramer Breaks Down the Complicated Story Behind CVS Health’s (CVS) Decline - Yahoo Finance | Jim Cramer Breaks Down the Complicated Story Behind CVS Health’s (CVS) Decline Yahoo Finance | View source ↗ | Yahoo Finance | Oct 10, 2026 | neutral | 0 | 0.6 |
| CVS Says Its Star Ratings Are Strong. TD Cowen Sees a $0.41 Earnings Hit - TIKR.com | CVS Says Its Star Ratings Are Strong. TD Cowen Sees a $0.41 Earnings Hit TIKR.com | View source ↗ | TIKR.com | Oct 10, 2026 | neutral | 0 | 0.6 |
| CVS Stock Dips After Drop in Medicare Advantage Plan Ratings - Barron's | CVS Stock Dips After Drop in Medicare Advantage Plan Ratings Barron's | View source ↗ | Barron's | Oct 9, 2026 | neutral | 0 | 0.6 |
| CVS Stock Dips After Drop in Medicare Advantage Plan Ratings -- Barrons.com - Moomoo | CVS Stock Dips After Drop in Medicare Advantage Plan Ratings -- Barrons.com Moomoo | View source ↗ | Moomoo | Oct 9, 2026 | neutral | 0 | 0.6 |
| What's Going On With CVS Health Stock Friday? - CVS Health (NYSE:CVS) - Benzinga | What's Going On With CVS Health Stock Friday? - CVS Health (NYSE:CVS) Benzinga | View source ↗ | Benzinga | Oct 9, 2026 | neutral | 0 | 0.6 |
| CVS Stock: TD Cowen Warns Of Bottom-Line Pressure For CVS Health Amid Star Ratings Setback - TradingView | CVS Stock: TD Cowen Warns Of Bottom-Line Pressure For CVS Health Amid Star Ratings Setback TradingView | View source ↗ | TradingView | Oct 9, 2026 | neutral | 0 | 0.6 |
| CVS stock faces headwind as Star ratings drop, TD Cowen says - Investing.com | CVS stock faces headwind as Star ratings drop, TD Cowen says Investing.com | View source ↗ | Investing.com | Oct 9, 2026 | neutral | 0 | 0.6 |
| CVS Health Trades at a Discount to Industry: How to Play the Stock? | CVS Health demonstrates attractive valuation and improving business performance, with Aetna's margin recovery gaining momentum and pharmacy segment showing strong prescription volume growth. However, 340B program pressures and expected Caremark membership declines pose near-term challenges. The stock trades at a discount to peers and has outperformed its industry, though technical indicators suggest weaker momentum. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | neutral | 0 | 1 |
| CVS Health Trades at a Discount to Industry: How to Play the Stock? | CVS Health demonstrates attractive valuation and improving business performance, with Aetna's margin recovery gaining momentum and pharmacy segment showing strong prescription volume growth. However, 340B program pressures and expected Caremark membership declines pose near-term challenges. The stock trades at a discount to peers and has outperformed its industry, though technical indicators suggest weaker momentum. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | neutral | 0 | 1 |
| Here's Why CVS Health (CVS) is a Strong Growth Stock | CVS Health is highlighted as a potential growth investment opportunity with a #3 (Hold) Zacks Rank and an A-rated VGM Score. The company demonstrates strong growth prospects with forecasted year-over-year earnings growth of 18.8% for the current fiscal year and recent upward earnings estimate revisions, making it worthy of consideration for growth-focused investors despite its Hold rating. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| Here's Why CVS Health (CVS) is a Strong Growth Stock | CVS Health is highlighted as a potential growth investment opportunity with a #3 (Hold) Zacks Rank and an A-rated VGM Score. The company demonstrates strong growth prospects with forecasted year-over-year earnings growth of 18.8% for the current fiscal year and recent upward earnings estimate revisions, making it worthy of consideration for growth-focused investors despite its Hold rating. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| Here's Why CVS Health (CVS) is a Strong Growth Stock | CVS Health is highlighted as a potential growth investment opportunity with a #3 (Hold) Zacks Rank and an A-rated VGM Score. The company demonstrates strong growth prospects with forecasted year-over-year earnings growth of 18.8% for the current fiscal year and recent upward earnings estimate revisions, making it worthy of consideration for growth-focused investors despite its Hold rating. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| CVS Health (CVS) Stock May Trade Below Fair Value On Integrated Care Push - Yahoo Finance | CVS Health (CVS) Stock May Trade Below Fair Value On Integrated Care Push Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| CVS Health (CVS) Advances While Market Declines: Some Information for Investors | CVS Health closed at $87.95, up 1.76% and outperforming the S&P 500's 0.22% loss. However, the stock has declined 10.03% over the past month, underperforming its Medical sector. The company is scheduled to report earnings on November 4, 2026, with forecasted EPS of $1.62 (up 1.25% YoY) and revenue of $105.04 billion (up 2.11% YoY). CVS currently holds a Zacks Rank of #3 (Hold) with a Forward P/E of 10.77, trading at a discount to its industry average. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | neutral | 0 | 1 |
| CVS will open nearly 20 pharmacies focused on prescriptions and pharmacist care in 2026. - Stock Titan | CVS will open nearly 20 pharmacies focused on prescriptions and pharmacist care in 2026. Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| Is Most-Watched Stock CVS Health Corporation (CVS) Worth Betting on Now? | CVS Health is rated Zacks Rank #3 (Hold) with mixed signals. While the stock has underperformed the S&P 500 by 11.4% over the past month, the company demonstrates strong fundamentals including consistent earnings and revenue beat history, solid revenue growth projections, and attractive valuation metrics with an A grade on the Value Style Score. However, recent earnings estimate revisions have been slightly negative, suggesting the stock may perform in line with the broader market in the near term. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | neutral | 0 | 1 |
| Jim Cramer on where he comes down on CVS Health's stock - CNBC | Jim Cramer on where he comes down on CVS Health's stock CNBC | View source ↗ | CNBC | Oct 6, 2026 | neutral | 0 | 0.6 |
| Distribution Deal Extension Could Be A Big Deal For CVS Stock (CVS) - Simply Wall Street | Distribution Deal Extension Could Be A Big Deal For CVS Stock (CVS) Simply Wall Street | View source ↗ | Simply Wall Street | Oct 5, 2026 | neutral | 0 | 0.6 |
| CVS Health (CVS) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance | CVS Health (CVS) Stock Declines While Market Improves: Some Information for Investors Yahoo Finance | View source ↗ | Yahoo Finance | Sep 21, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.